Indivior PLC
Dr. David Wheadon appointed Chair of
the Board
Richmond, VA, January 28, 2025 - The Board of Directors of Indivior PLC are pleased to
announce the appointment of Dr. David Wheadon as Chair of the Board
with immediate effect. Dr. Wheadon joined the Board as a
Non-Executive Director in June 2024. His appointment was
approved by the Board, following a succession process undertaken by
the Nomination Committee and led by Juliet Thompson, Lead
Independent Director.
Separately, and further to the
announcement of December 17, 2024, the Board is working with
Oaktree Capital Management LP to identify and appoint an additional
Non-Executive Director to the Board, which it expects to announce
shortly.
Previous to joining the Indivior
Board, Dr. Wheadon served as senior vice president of global
regulatory affairs, patient safety, and quality assurance at
AstraZeneca Plc from December 2014 to July 2019. Prior to that, he
was executive vice president, research and advocacy at Juvenile
Diabetes Research Foundation International Inc., from May 2013 to
December 2014, and senior vice president, scientific and regulatory
affairs at Pharmaceutical Research and Manufacturers of America
(PhRMA), from January 2009 to May 2013. Prior to that he served as
vice president, global pharmaceutical regulatory and medical
science, and group vice president, global pharmaceutical regulatory
affairs at Abbott Laboratories from 2005 to 2009 and held senior
regulatory and clinical development leadership positions at
GlaxoSmithKline Plc and Eli Lilly and Company.
Dr. Wheadon received his M.D. from
Johns Hopkins University School of Medicine and an A.B. in Biology
from Harvard University. He completed his postdoctoral
training in Psychiatry at Tufts/New England Medical Center in
Boston, Massachusetts.
Dr. Wheadon is a Non-Executive
Independent Director of Sotera Health Company and Vaxart, Inc. He
also serves as a member of the Board of Trustees of Mount Sinai
Health System.
Dr. Wheadon is currently a member of
the Compensation, Nomination, and Science Committees. Dr. Wheadon
has also been appointed Chair of the Nomination
Committee.
Comment by Juliet Thompson,
Lead Independent Director
I
am delighted to announce David's appointment as Chair of the Board
and am confident he will bring strong leadership to the role,
leveraging his track record across specialty pharma and
beyond. David has already established himself as a valued
member of the Board and we look forward to benefitting from his
continued insights and deep strategic and operational experience as
we work together to deliver value to all Indivior
stakeholders.
Comment by Dr. David Wheadon,
Chair of the Board of Indivior PLC
It
is an honor to become Chair of the Board of Indivior. This is a
great company which is unwavering in its mission to help change
patients' lives by pioneering life-transforming treatment for
opioid use disorder. I am very proud to be appointed to lead the
Board and support that mission.
I
look forward to working closely with the Board and management team
to leverage Indivior's deep expertise, long track record and strong
culture. As a Board, we are determined to help realize the
Company's great potential and deliver value for shareholders and
our wider stakeholders.
About
Indivior
Indivior is a global pharmaceutical
company working to help change patients' lives by developing
medicines to treat substance use disorders (SUD). Our vision is
that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to expand on its heritage in this category. Headquartered in the
United States in Richmond, VA, Indivior employs over 1,000
individuals globally and its portfolio of products is available in
over 30 countries worldwide. Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Investor Enquiries:
Jason Thompson
VP, Investor Relations
Indivior PLC
+1 804 402 7123
jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Indivior PLC
+1 804 263 3978
timothy.owens@indivior.com
Media Enquiries:
For Indivior:
Jonathan Sibun
Teneo
+44 (0)20 7353 4200
Indiviormediacontacts@indivior.com
Tim Lynch / Maggie
Carangelo
Joele Frank, Wilkinson Brimmer
Katcher
+1 212 895 8600
